Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, B3000, Belgium; Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, KU Leuven, Leuven, B3000, Belgium.
Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, B3000, Belgium; Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, KU Leuven, Leuven, B3000, Belgium.
Curr Opin Biotechnol. 2021 Apr;68:124-143. doi: 10.1016/j.copbio.2020.10.011. Epub 2020 Nov 26.
Cancer immunotherapy aims to augment the response of the patient's own immune system against cancer cells. Despite effective for some patients and some cancer types, the therapeutic efficacy of this treatment is limited by the composition of the tumor microenvironment (TME), which is not well-suited for the fitness of anti-tumoral immune cells. However, the TME differs between cancer types and tissues, thus complicating the possibility of the development of therapies that would be effective in a large range of patients. A possible scenario is that each type of cancer cell, granted by its own mutations and reminiscent of the functions of the tissue of origin, has a specific metabolism that will impinge on the metabolic composition of the TME, which in turn specifically affects T cell fitness. Therefore, targeting cancer or T cell metabolism could increase the efficacy and specificity of existing immunotherapies, improving disease outcome and minimizing adverse reactions.
癌症免疫疗法旨在增强患者自身免疫系统对癌细胞的反应。尽管这种治疗方法对一些患者和某些癌症类型有效,但它的治疗效果受到肿瘤微环境(TME)组成的限制,TME 并不适合抗肿瘤免疫细胞的适应性。然而,TME 在癌症类型和组织之间存在差异,因此,开发对大量患者有效的治疗方法的可能性变得复杂。一种可能的情况是,每种癌细胞因其自身的突变和起源组织的功能而具有特定的代谢,这将影响 TME 的代谢组成,进而特异性地影响 T 细胞的适应性。因此,针对癌症或 T 细胞代谢可能会提高现有免疫疗法的疗效和特异性,改善疾病结局并最小化不良反应。